Montero CLB, Quesada RMA

Language: Spanish
References: 21
Page: 105-110
PDF size: 333.04 Kb.

ABSTRACT

Long QT syndrome (LQTS) is an abnormality of the cardiac conduction system that affects the ventricular repolarization. This abnormality might be congenital and frequently associated with a hereditary pattern or could be acquired, secondary to the use of some medications. This syndrome is associated with cardiogenic syncope, ventricular arrythmias and even sudden death. Due to the increase in the recognition of this disease, the primary care physicians are likely to find themselves encountering challenging management decisions. This review analyzes definitions, etiologic, clinical and therapeutic aspects of this syndrome.

REFERENCES

1. Antzelevitch C. Arrhythmogenic mechanisms of QT prolonging drugs: Is QT prolongation really the problem? J Electrocardiol 2004; 37 Suppl: 15-24

2. Arizona Center for Education and Research on TherapeuticsThe Critical Path Institute. [Internet] Revisado: 03/25/2008. Disponible en www.qtdrugs.org

3. Berul C. Congenital Long-QT Syndromes: Who’s at Risk for Sudden Cardiac Death? Circulation 2008;117;2178-2180

4. Contreras E, Gomez J, Zuluaga S. Síndrome de QT largo.Rev Colomb Cardiol 2008; 15: 12-17)

5. Chiang CE, Roden DM: The long QT syndromes: genetic basis and clinical implications. J Am Coll Cardiol 2000 Jul; 36(1): 1-12

6. Goldenberg I, Moss AJ, Zareba W. Sudden cardiac death without structural heart disease: update on the long QT and Brugada syndromes. Curr Cardiol Rep 2005 Sep; 7(5):349-56.

7. Gutiérrez O, Araya V. Manual de arritmias cardiacas: Guía diagnóstica y terapéutica. Editorial Universidad de Costa Rica, 2002

8. Hofman N, Wilde A, Van Langen I et al. Diagnostic criteria for congenital long QT syndrome in the era of molecular genetics: do we need a scoring system? European Heart Journal 2007 28(5):575-580

9. Levine E, Spencer D, Rosero A, Budzikowski A. Moss A. Zareba W. Daubert J. Congenital long QT syndrome: Considerations for primary Care physicians. Cleveland Clinic Journal of Medicine. Volume 75, august 2008.

10. Madeiros A. Clinical and genetic characteristics of long QT syndrome. Rev Esp Cardiol 2007; 60 (7): 739-52.

11. Mönnig G, Eckardt L, Wedekind H, Haverkamp W, Gerss J, Milberg P, Wasmer K, Kirchhof P, Assmann G, Breithardt G, Schulze-Bahr E. Electrocardiographic risk stratification in families with congenital long QT syndrome. Eur Heart J. 2006.

12. Moss A, Zareba W, Hall J, Schwartz P, Crampton R. Benhorin J, Vincent M. Effectiveness and Limitations of b-Blocker Therapy in Congenital Long-QT Syndrome. Circulation. 2000;101:616-623.

13. Napolitano C, Priori SG, Schwartz PJ, et al. Genetic testing in the Long QT syndrome: development and validation of an efficient Approach to genotyping in clinical practice. JAMA 2005; 294:2975– 2980.

14. Roden DM. Long-QT syndrome. N Eng J Med. 2008;358:169 –176.

15. Sovari A, Cocheril A, Assadi R, Zareba W, Rosero S. Long QT Syndrome. January 3, 2007. E-medicine. [Internet] Disponible en www.emedicine.com/MED/topic1983.htm

16. Schwartz P, Priori G, Spazzolini S, Moss A, Vincent M. Genotype-Phenotype Correlation in the Long-QT Síndrome. Gene-Specific Triggers for Life-Threatening Arrhythmias Circulation. 2001;103:89.

17. Schwartz PJ, Moss AJ, Michael Vincent GM, Crampton RS. Diagnostic criteria for the long QT syndrome—an update. Circulation 1993;88: 782–784.

18. Sauer AJ, Moss AJ, Mcnitt S, et al. Long QT syndrome in adults. JAm Coll Cardiol 2007; 49:329–337.

19. Tong K L, Lau Y S, W S Teo A Case Series of Drug-Induced LongQT Syndrome and Torsade de Pointes. Singapore Med J 2001 Vol 42(12) : 566-570

20. Zabera W. Role of implantable cardioverter defibrillator therapy in patients with Long QT syndrome. Am Heart J 2007; 153 (4 Suppl): 53-8.

21. Zareba W, Moss AJ, Daubert JP, et al. Implantable cardioverter Defibrillator in high-risk long QT syndrome patients. J Cardiovasc Electrophysiol 2003; 14:337–341.